Urodynamics
Urodynamics (UDS) is the dynamic study of the transport, storage, and evacuation of urine through the measurement of relevant physiological parameters. The term was coined in 1954 by Dr. David Davis to describe scientific observation of lower urinary tract (LUT) function. The primary clinical goal of urodynamic evaluation is to reproduce a patient's symptomatic complaints in a laboratory setting while collecting objective physiological data to provide a pathophysiological explanation for those symptoms.
Unlike most diagnostic tests, urodynamics is an interactive study — not a passive measurement. It is indicated when an accurate diagnosis is needed to direct treatment that cannot be reliably determined by history and physical examination alone: when empiric treatments have failed, when lower urinary tract disease risks causing upper tract deterioration (renal failure), or when considering invasive and irreversible surgical interventions.
:::note Core Principle Patient-reported symptoms are often unreliable witnesses to underlying pathology. A high-flow, low-pressure voiding study may explain why a patient's "slow stream" is actually obstructed; a normal-appearing cystometry may reveal that urgency incontinence is neurogenic in origin. UDS provides the mechanistic diagnosis. :::
Components of Urodynamic Testing
The ICS standard urodynamic protocol comprises clinical history with symptom scores, physical examination, 3-day voiding diary, uroflowmetry with post-void residual (PVR), and cystometry with pressure-flow study.[2]
1. Uroflowmetry (Non-invasive)
A non-invasive measurement of urine flow rate over time during spontaneous voiding.
- Normal pattern: Smooth, bell-shaped arc with rapid rise to peak and symmetric descent
- Obstructive pattern: Plateau-shaped or prolonged flow with reduced peak
- Underactive detrusor: May produce an intermittent or prolonged flat curve
Limitation: Cannot distinguish between bladder outlet obstruction and detrusor underactivity — both produce low flow. Invasive pressure studies are required for differentiation.
Combined with PVR (by ultrasound or catheterization), uroflowmetry screens for voiding dysfunction and guides the need for further testing.
2. Cystometry
Graphic depiction of bladder and abdominal pressure relative to infused volume during filling, storage, and voiding. The multichannel cystometrogram uses:
- Pves — intravesical pressure (from bladder catheter)
- Pabd — intra-abdominal pressure (from rectal or vaginal catheter)
- Pdet — detrusor pressure (calculated: Pves − Pabd)
Zeroing and reference: All transducers are zeroed to atmospheric pressure and positioned at the level of the pubic symphysis.
Normal baseline pressures by position:
| Position | Pves / Pabd (cm H₂O) | Pdet (cm H₂O) |
|---|---|---|
| Supine | 5–20 | −5 to +5 |
| Sitting | 15–40 | −5 to +5 |
| Standing | 30–50 | −5 to +5 |
Filling phase assessments:
- Sensation: First Sensation of Filling (FSF), First Desire to Void (FDV), Strong Desire to Void (SDV)
- Compliance: ΔVolume ÷ ΔPdet (normal: large volume change with minimal pressure rise)
- Detrusor overactivity: Involuntary phasic rises in Pdet during filling
- Cystometric capacity: Volume at end of filling study (voided volume + PVR); normal adult capacity ~350–600 mL
3. Pressure-Flow Study (Voiding Phase)
Simultaneous measurement of detrusor pressure and flow rate during voiding.
Key parameters:
- Qmax — Maximum flow rate (varies by age and gender; generally ≥15 mL/s in adult males)
- Pdet at Qmax — Detrusor pressure at the moment of maximum flow
- Opening pressure — Pdet at which flow begins (Point A on tracing)
- Opening time — Time from permission to void to flow onset (Point B)
Nomograms for obstruction grading in men:
- Abrams-Griffiths nomogram: Classifies as obstructed, equivocal, or unobstructed based on Pdet@Qmax vs. Qmax
- Schäfer bladder outlet obstruction index (BOOI): BOOI = Pdet@Qmax − 2(Qmax); ≥40 = obstructed; <20 = unobstructed
- Bladder contractility index (BCI): BCI = Pdet@Qmax + 5(Qmax); assesses detrusor contractile strength
4. Videourodynamics (VUDS)
Combines multichannel pressure-flow studies with simultaneous fluoroscopic imaging of the bladder and urethra.
Additional information provided:
- Anatomical localization of bladder outlet obstruction (bladder neck vs. sphincter level vs. urethra)
- Visualization of vesicoureteral reflux (VUR) during filling
- Morphology of the bladder (trabeculation, diverticula)
- Urethral anatomy during voiding
Indications for VUDS over standard UDS:
- Neurogenic lower urinary tract dysfunction (definitive assessment of storage pressures + upper tract risk)
- Complex posterior urethral pathology
- Evaluation after failed surgery
- Suspected vesicoureteral reflux
5. Urethral Function Tests
Urethral pressure profile (UPP) and Valsalva/cough leak point pressure (VLPP/CLPP):
- Assess outlet resistance and sphincteric competence
- Demonstrate considerable test-retest variation and overlap between normal and pathological measurements
- VLPP correlates weakly with incontinence severity and does not reliably predict surgical outcomes
- No reliable cutoff predicts continence surgery failure[1]
Clinical utility: Limited as standalone tests; most useful in context of full multichannel study.
6. Electromyography (EMG)
Measures neuromuscular activity of pelvic floor musculature and urethral sphincter during filling and voiding.
Primary role: Detection of detrusor-sphincter dyssynergia (DSD) — simultaneous contraction of detrusor and external sphincter, characteristic of suprasacral spinal cord lesions. Surface EMG electrodes or needle electrodes can be used; surface patch electrodes (perineal or anal) are used most commonly in clinical urodynamics.
The "9 Cs" Framework for UDS Interpretation
A systematic approach to reviewing a urodynamic study:
| C | Parameter | What You're Assessing |
|---|---|---|
| Contractions | Detrusor overactivity | Involuntary phasic Pdet rises during filling |
| Compliance | Bladder wall viscoelasticity | ΔV/ΔPdet; sustained pressure elevation ≥40 cm H₂O = upper tract risk |
| Continence | Sphincteric competence | Leak with cough/Valsalva in absence of detrusor contraction = SUI |
| Capacity | Cystometric capacity | Volume at end of study; low = hypersensitive bladder or reduced compliance |
| Sensation | Sensory thresholds | FSF, FDV, SDV — early = hypersensitivity; absent = impaired afferent function |
| Contractility | Detrusor strength | BCI; weak or absent contraction = underactive detrusor |
| Coordination | DSD assessment | EMG activity during voiding contraction = dyssynergia |
| Complete Emptying | Post-void residual | Elevated PVR after voiding = incomplete emptying |
| Clinical Obstruction | BOO grading | BOOI, Abrams-Griffiths, Schäfer nomogram |
Classic Urodynamic Signatures
Bladder Outlet Obstruction (BOO)
Hallmark: High Pdet in the presence of low Qmax.
- BOOI ≥40 cm H₂O = obstructed (men)
- May also see high bladder capacity, detrusor overactivity (secondary to obstruction), reduced compliance
- Etiology determined by VUDS: benign prostatic enlargement (most common in older men), urethral stricture, bladder neck contracture, dysfunctional voiding
- BOO in females: less common; urethral stenosis, prior anti-incontinence surgery, or pelvic organ prolapse
Detrusor Overactivity (DO)
Involuntary phasic detrusor contractions (Pdet rises) occurring during the filling phase, with or without associated urgency or incontinence.
- Idiopathic DO: No identified neurological cause
- Neurogenic DO (NDO): Associated with known neurological condition (suprasacral spinal cord injury, multiple sclerosis, Parkinson's, stroke)
NDO in spinal cord injury is clinically critical: high-amplitude contractions + DSD + reduced compliance = significant upper tract risk.
Low Bladder Compliance
A tonic, continuous rise in Pdet as the bladder fills — without phasic contractions. Indicates fibrotic or poorly compliant bladder wall.
:::warning Upper Tract Risk Threshold Sustained intravesical storage pressures exceeding 40 cm H₂O are a high-risk threshold for upper urinary tract damage and renal failure — particularly in patients with neurogenic bladder. This threshold, established from the landmark work of McGuire et al. (1981), drives urological surveillance and treatment decisions in spinal cord injury and myelomeningocele populations.[3] :::
Detrusor Underactivity (DUA)
A detrusor contraction of reduced strength or duration, resulting in prolonged voiding, incomplete emptying, or inability to void.
- BCI <100 = underactive
- Must be distinguished from BOO — both produce low Qmax, but DUA has low Pdet@Qmax while BOO has high Pdet@Qmax
- Clinically important before offering surgical outlet reduction procedures in men
Detrusor-External Sphincter Dyssynergia (DSD)
Involuntary contraction of the external urethral sphincter coinciding with a detrusor contraction during voiding. Characteristic of suprasacral spinal cord lesions.
Consequences:
- Functional outlet obstruction → high voiding pressures
- Upper tract risk (hydronephrosis, VUR, renal failure)
- Autonomic dysreflexia in cervical/high thoracic injuries
Identified on EMG during pressure-flow study; confirmed anatomically by VUDS.
Stress Urinary Incontinence (SUI)
Involuntary leakage of urine during filling cystometry associated with increased abdominal pressure (cough, Valsalva, heel drop) in the absence of a detrusor contraction.
On the tracing: Pves and Pabd rise simultaneously → Pdet is unchanged → leakage occurs via the urethra.
Distinguishing genuine SUI from DO-related leakage (urgency incontinence) is the key diagnostic question — and the one UDS is specifically designed to answer.
Fowler's Syndrome
A condition in young women causing unexplained, often painless, urinary retention associated with abnormal urethral sphincter EMG activity (complex repetitive discharges and decelerating bursts). The sphincter fails to relax appropriately for voiding, generating abnormally high urethral closure pressures. Described by Clare Fowler (PMID: 3771764). Diagnosis requires sphincter needle EMG; responds to sacral neuromodulation.
Technical Standards and Quality Control
Per ICS Good Urodynamic Practices 2016–2018:[2][5]
- Liquid-filled catheters connected to pressure transducers positioned at the level of the pubic symphysis with atmospheric pressure as zero reference
- Quality of recording must be monitored throughout the study — not just reviewed at the end
- Provocations (cough tests, positional changes, running water) should reproduce the patient's specific symptoms
- Artifacts must be identified and not allowed to confound interpretation: rectal contractions (false Pdet drops), catheter movement artifacts ("knock" artifacts), signal dampening
- Equipment must be calibrated per manufacturer specifications
Labeled tracing points:
- A = Opening Detrusor Pressure (Pdet at which flow begins)
- B = Opening Time
- C = Qmax (Maximum Flow Rate)
- D = Pdet at Qmax
Clinical Indications and Guidelines
When UDS Should NOT Be Routinely Performed
Uncomplicated stress urinary incontinence (SUI) in women:
The VALUE trial (Nager et al., NEJM 2012) — the largest RCT on preoperative UDS in SUI — demonstrated that basic office evaluation was non-inferior to urodynamic testing for one-year surgical outcomes in women with uncomplicated SUI.[6]
ACOG (Practice Bulletin 155, 2015): "Preoperative multichannel urodynamic testing is not necessary before planning primary anti-incontinence surgery in women with uncomplicated SUI."[1]
Overactive bladder (OAB) — initial evaluation:
AUA/SUFU OAB Guideline (2024): "Clinicians should not routinely perform urodynamics in the initial evaluation of patients with OAB, as there are no pathognomonic urodynamic findings that confirm the diagnosis."[7]
Low-risk neurogenic LUTD — initial evaluation:
AUA/SUFU NLUTD Guideline (2021): Multichannel UDS are unlikely to add significant value when storage pressures are generally not elevated (e.g., incomplete lower motor neuron lesions, MS without voiding symptoms).[8]
When UDS IS Indicated
| Clinical Scenario | Rationale |
|---|---|
| Complicated SUI: mixed incontinence, prior surgery, voiding dysfunction, significant prolapse | Preoperative UDS can anticipate post-op outcomes; EUGA recommends in these cases[9] |
| Men with voiding dysfunction | Distinguish BOO from DUA — management differs significantly (TURP vs. watchful waiting vs. CIC) |
| Unknown-risk or high-risk neurogenic LUTD | Essential for detrusor leak point pressure, compliance assessment, upper tract risk stratification[8] |
| Spinal cord injury / myelomeningocele | Upper tract surveillance; guide CIC, anticholinergic, or sphincteric management |
| Failed prior continence surgery | Diagnose DUA, new DO, or persistent SUI |
| Diagnostic uncertainty after initial workup | Clarify diagnosis when symptoms and initial studies are discordant |
| Before irreversible surgical intervention | Especially augmentation cystoplasty, urinary diversion, sphincter surgery |
Evidence on UDS and Outcomes
Randomized Controlled Trial Data
A meta-analysis of 7 RCTs (n=1,149 women) undergoing surgical management of SUI showed no significant difference in patient-reported success (RR 1.01, 95% CI 0.88–1.16) or objective success (RR 1.02, 95% CI 0.95–1.08) between UDS-guided and clinical-evaluation-only groups. No difference in voiding dysfunction, de novo urgency, or UTI rates.[10]
A Cochrane review of 8 trials found that while UDS changed clinical decision-making in 17% vs. 3% of cases (RR 5.07), this did not translate to improved continence outcomes at one year (37% vs. 36% incontinent; NNT = 100).[11]
Impact on Physician Confidence
Despite limited outcome improvement in uncomplicated cases, UDS influences clinical thinking. In a prospective tertiary referral study (n=102), UDS resulted in a management change in 78% of patients, with mean physician confidence increasing from 2.9 to 4.1 (on a 0–5 scale).[12]
Predictive Value
- Pre-existing DO is associated with increased post-operative OAB after continence surgery
- Pre-existing voiding dysfunction predicts post-operative voiding difficulty
- These findings, though identified by UDS, have not been shown to improve outcomes when used to guide decisions[9]
Complications and Tolerability
Primary risk: Urethral catheterization — dysuria and urinary tract infection.
- Symptomatic UTI following cystometry: estimated ≥3% incidence[4][13]
- Prospective study (n=119): overall complication rate 19.0% in men vs. 1.8% in women; 4.8% post-study urinary retention (all had significant BOO); 6.2% significant UTI in men[14]
- Questionnaire study (n=154): mean pain 2.27/10, embarrassment 2.59/10; despite this, 73.6% of men and 80.6% of women were willing to repeat UDS[15]
Antibiotic prophylaxis: Reduces bacteriuria (4% vs. 12% without) but the reduction in symptomatic UTI (20% vs. 28%) did not reach statistical significance in a Cochrane review of 9 trials (n=973). Use is institution-dependent — many centers prophylax high-risk patients (neurogenic bladder, recurrent UTI, prior catheterization).[16]
Ambulatory Urodynamic Monitoring (AUM)
AUM uses physiological anterograde filling (natural diuresis) and longer observation periods compared to traditional retrograde-fill laboratory UDS — providing a more physiologically authentic evaluation of voiding behavior.
Indications: Unexplained urinary symptoms with non-diagnostic standard UDS; suspected DO not captured in brief laboratory study.
Limitations: Retrograde calibration more difficult; longer duration; requires patient cooperation.
Telemetric AUM (TAUM): Emerging wireless, catheter-free, battery-powered devices monitoring bladder pressure and volume during daily activities. Under active investigation with innovations in remote monitoring, rechargeable energy sources, and materials engineering — potentially transforming ambulatory urodynamic diagnosis.[17]
Summary of Guideline Recommendations
| Guideline | Setting | Recommendation |
|---|---|---|
| ACOG Practice Bulletin 155 (2015) | Uncomplicated SUI in women before primary surgery | UDS not necessary |
| AUA/SUFU OAB (2024) | Initial evaluation of OAB | UDS should not be routinely performed |
| AUA/SUFU NLUTD (2021) | Low-risk neurogenic LUTD at initial evaluation | UDS should not be routinely performed |
| AUA/SUFU NLUTD (2021) | Unknown-risk / high-risk neurogenic LUTD | Should obtain multichannel UDS with DLPP |
| EUGA Position Statement (2024) | Uncomplicated SUI | Evidence does not support systematic UDS |
| EUGA Position Statement (2024) | Complicated SUI (mixed sx, prior surgery, prolapse, voiding dysfunction) | Preoperative UDS advised |
| ICS Good Urodynamic Practices (2016–2018) | Technical standards | Comprehensive standards for performance, interpretation, and reporting |
References
1. ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. Obstet Gynecol. 2015;126(5):e66–e81. [doi:10.1097/AOG.0000000000001148]
2. Drake MJ, Doumouchtsis SK, Hashim H, Gammie A. "Fundamentals of Urodynamic Practice, Based on International Continence Society Good Urodynamic Practices Recommendations." Neurourol Urodyn. 2018;37(S6):S50–S60. [doi:10.1002/nau.23773]
3. McGuire EJ, Woodside JR, Borden TA, Weiss RM. "Prognostic value of urodynamic testing in myelodysplastic patients." J Urol. 1981;126(2):205–209. [PMID: 7196460]
4. Clement KD, Burden H, Warren K, et al. "Invasive Urodynamic Studies for the Management of Lower Urinary Tract Symptoms (LUTS) in Men With Voiding Dysfunction." Cochrane Database Syst Rev. 2015;(4):CD011179. [doi:10.1002/14651858.CD011179.pub2]
5. Rosier PFWM, Schaefer W, Lose G, et al. "International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, Uroflowmetry, Cystometry, and Pressure-Flow Study." Neurourol Urodyn. 2017;36(5):1243–1260. [doi:10.1002/nau.23124]
6. Nager CW, Brubaker L, Litman HJ, et al. "A Randomized Trial of Urodynamic Testing before Stress-Incontinence Surgery." N Engl J Med. 2012;366(21):1987–1997. [doi:10.1056/NEJMoa1113595]
7. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11–20. [doi:10.1097/JU.0000000000003985]
8. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. [doi:10.1097/JU.0000000000002235]
9. Ruffolo AF, Tsiapakidou S, Daykan Y, et al. "European Urogynaecological Association Position Statement: The Role of Urodynamics in Stress Urinary Incontinence Evaluation and Treatment Decision." Eur J Obstet Gynecol Reprod Biol. 2024;297:176–181. [doi:10.1016/j.ejogrb.2024.04.024]
10. Lor KY, Soupashi M, Abdel-Fattah M, Mostafa A. "Does Pre-Operative Urodynamics Lead to Better Outcomes in Management of Urinary Incontinence in Women? A Linked Systematic Review and Meta-Analysis." Eur J Obstet Gynecol Reprod Biol. 2020;244:141–153. [doi:10.1016/j.ejogrb.2019.11.013]
11. Clement KD, Lapitan MC, Omar MI, Glazener CM. "Urodynamic Studies for Management of Urinary Incontinence in Children and Adults." Cochrane Database Syst Rev. 2013;(10):CD003195. [doi:10.1002/14651858.CD003195.pub3]
12. Malik RD, Hess DS, Carmel ME, Lemack GE, Zimmern PE. "Prospective Evaluation of Urodynamic Utility in a Subspecialty Tertiary Practice." Urology. 2019;126:59–64. [doi:10.1016/j.urology.2019.01.004]
13. Glazener CM, Lapitan MC. "Urodynamic Investigations for Management of Urinary Incontinence in Adults." Cochrane Database Syst Rev. 2002;(3):CD003195. [doi:10.1002/14651858.CD003195]
14. Klingler HC, Madersbacher S, Djavan B, et al. "Morbidity of the Evaluation of the Lower Urinary Tract With Transurethral Multichannel Pressure-Flow Studies." J Urol. 1998;159(1):191–194. [doi:10.1016/S0022-5347(01)64054-0]
15. Yokoyama T, Nozaki K, Nose H, et al. "Tolerability and Morbidity of Urodynamic Testing: A Questionnaire-Based Study." Urology. 2005;66(1):74–76. [doi:10.1016/j.urology.2005.01.027]
16. Foon R, Toozs-Hobson P, Latthe P. "Prophylactic Antibiotics to Reduce the Risk of Urinary Tract Infections After Urodynamic Studies." Cochrane Database Syst Rev. 2012;10:CD008224. [doi:10.1002/14651858.CD008224.pub2]
17. Abelson B, Majerus S, Sun D, et al. "Ambulatory Urodynamic Monitoring: State of the Art and Future Directions." Nat Rev Urol. 2019;16(5):291–301. [doi:10.1038/s41585-019-0175-5]